Recommendations on prevention and management of malignancy in inflammatory bowel disease

Differences between the inflammatory bowel disease guidelines in the United Kingdom and outside the United Kingdom

Monitoring disease activity and optimizing drugs for patients with inflammatory bowel disease

MDT I

MDT II

MDT III

Benefits and challenges of Treat-to-Target in Crohn’s disease

Histologic healing and prognosis in CD

Transmural healing: honey or trap for endpoints of Crohn’s disease

Monitoring adverse events for JAKi in inflammatory bowel disease

Integrating novel and emerging S1PRs into clinical practice of inflammatory bowel disease

Therapeutic options beyond JAKi and S1PRs in small molecules: what else can we expect?

China Voice: IUS for Excellence in IBD Management

Hands-on Workshop

Defining and avoiding low value care in IBD

Early life risk factors for inflammatory bowel disease

Natural course of IBD: East vs. West

Special aspects of IBD in the elderly

Real-world comparative effectiveness and safety of filgotinib and upadacitinib for ulcerative colitis

Epidemiology of primary sclerosing cholangitis among patients with inflammatory bowel disease in Asian countnes:An international muticenter retrospective study

Biomarkers for personalizing and precision IBD therapies

Artificial intelligence in prognosis and precision medicine for inflammatory bowel disease

Nanomedicine-mediated drug delivery for potential treatment of inflammatory bowel disease

Autotaxin induces S1P/S1PR1 signaling to affect Th17/Treg cell balance and exacerbate intestinal inflammation in colitis

Machine learning models for predicting ustekinumab response in Crohn's disease patients based on pathological features

How to choose a second biologic agent for Crohn’s disease: the state of the art

Is there a superior first line biological/small molecule in CD: positioning advanced therapy in the treatment of CD

Treatment of perianal fistulizing crohn's diseae: emerging evidence and clinical application

Speed of early symptomatic remission with advanced biological therapies for moderate-to-severe ulcerative colitis

Current evidence for combined targeted therapy for the treatment of IBD and EIM

An eye on eye: when and how to rescue ocular manifestations of inflammatory bowel disease

Arthropathic manifestations of inflammatory bowel disease: potential therapeutic approaches

Inflammatory bowel disease and primary sclerosing cholangitis: emerging therapy according to dominant behavior

Research progress on dietary factors, intestinal flora and the pathogenesis of inflammatory bowel disease

Prevalence of and factors associated with extraintestinal manifestations induced by biologics

Challenge case I

Challenge case II

Challenge case III

Challenge case IV

Challenge case V

Challenge case VI

Difficult-to-treat inflammatory bowel disease: the definition

Role of intestinal mucosal barrier in inflammatory bowel disease

Gut microbiota and metabolites as predictors of drug response in IBD

Non-coding RNAs as emerging biomarkers and therapeutic targets for CD

Macrophage RNF2 facilitates colonic infammation through inhibition of RUNX3/ACSL1 axis-mediated monocyte-macrophage differentiation

Artificial intelligence-based fingerprint index of visceral adipose tissue for prediction of intestinal damage in patients with Crohn's disease

Assembling the future through JAK inhibition: creating a better everyday in IBD

UC histological remission: it is time to take this step now

Achieve mucosal healing: It's time to initiate biologics earlier

Shall we raise the concentration of novel biological agents to subdue perianal fistula in Crohn’s disease

Effectiveness and safety of IL12/23 and IL23 antibodies in fistula behavior in Crohn’s disease

Biologic and exploratory drugs for Crohn's-related enterocutaneous fistula in real-world practice

Optimizing stem cell treatment for complex perianal fistula in CD

Surgical consideration in the treatment of complex perianal fistula from CD

Postoperative intestinal fistula: how to avoid, and surgical rescue

Clinically predicting primary and secondary loss of response - current opinion and future perspectives

Impact of genotype in Immunogenicity and failure to treatment with biologics in IBD

Biologic therapy for inflammatory bowel disease: Real-world effectiveness and impact of drug sequencing after primary loss of response

Small molecule drugs as salvage therapy in moderate-to-severe UC patients without response to biologic agent

Small molecules beside JAKs: what shall we know currently and in the future?

Emerging strategy to initial enhance or re-capture responses for CD patients failing novel biologic agents

Global consensus for pregnancy and lBD

Gut-brain axis interacts with immunomodulation in inflammatory bowel disease

Crosstalk between the MAPK and WNT pathways in inflammatory bowel diseases

Unraveling the crosstalk of gut-liver axis between IBD and autoimmune liver diseases

Incidence, risk factors and outcomes of chronic antibiotic-refractory pouchitis in Korean ulcerative colitis patients: asingle center retrospective study

hUC-MSCs therapy for Crohn's disease: efficacy in TNBS-induced colitis in rats and pilot clinical study

FMT: choose the right microbiota and patients

FMT: lack of evidence in IBD to date

Hyperbaric oxygen therapy: off-label management for perianal fistulizing Crohn’s disease

Hyperbaric oxygen therapy: extending therapy for ulcerative colitis

5-ASA on biologics: when to stop, how to stop?

5-ASA on biologics: can we continue, why we continue?

Mechanistic perspective: anti-Inflammatory and anticancer effects of Mesalazine

Selective Sphingosine 1-phosphate receptor modulators – Etrasimod-Opening a new era in UC treatment

Combination of 5-ASA and biological agents: exploring complementary mechanisms and benefits

Additional benefits from enteral nutrition combined with biologics

Risk of infection in elderly patients with inflammatory bowel disease using biologics

Risk of TB and HBV reactivation in patients with IBD on novel biologics

JAKi downregulate antiviral immune defense: current situation and overwhelm

Drugs targeting the interleukin pathway: the present and future

Combination therapy in children with IBD

Application scenarios and prospectives of combination therapy of small molecule drugs and biological agents

What we still have: combination therapy beside bio-bio or bio-SMD?

Altered CD4+T cell reactivity against yeasts in ASCA positive patients with Crohn's disease

Trace element deficiency in lBD patients-a cross-sectional study

Recent advances in cross-sectional imaging for assessing stricturing Crohn’s disease

Novel endoscopic management for stricturing Crohn’s disease

Novel biologics, small molecules or mesenchymal stem cell therapy as therapeutic choices for stricturing Crohn’s disease

The advantageous position of Chinese patent drugs in treatment of UC

Infliximab biosimilar therapy as a clinical treatment strategy for inflammatory bowel disease

Intestinal targeted biologic agent as the foundation for combination therapy with small molecule drugs: the prospectives

Treatment strategies for luminal inflammatory CD: What's the difference

Next Target of IBD in Asia – update Asian guidelines with the development of pharmacology

Next Target of IBD in Asia – factors improving the quality of care

Next Target of IBD in Asia – establishing a pharmacoeconomic system

Panel discussion